Investigating the effect of rose hip alcoholic extract on the ventricular arrhythmia in heart failure patients with Implantable Cardioverter Defibrillator

开始日期2024-07-05

申办/合作机构

Mashhad University of Medical Sciences

IRCT20220516054874N16 / Recruiting临床3期IIT

Investigating the effect of pentoxifylline on ventricular arrhythmia in heart failure patients with Implantable Cardioverter Defibrillator

开始日期2024-06-04

申办/合作机构

Mashhad University of Medical Sciences

CTRI/2022/11/047683 / Not yet recruitingN/AIIT

Understanding the association of periodontitis and atrial tachyarrhythmia â?? A molecular and biochemical study

开始日期2023-02-02

申办/合作机构-

100 项与阵发性心动过速相关的临床结果

登录后查看更多信息

100 项与阵发性心动过速相关的转化医学

登录后查看更多信息

0 项与阵发性心动过速相关的专利（医药）

登录后查看更多信息

2,476

项与阵发性心动过速相关的文献（医药）

2024-10-01·Heart Rhythm

Heart transplantation for pediatric patients with malignant arrhythmias: Indications and Outcomes

Article

作者: Kirklin, James K ; Wittlieb-Weber, Carol A ; Hoffman, Timothy M. ; Azeka, Estela ; Weisert, Molly ; Hoffman, Timothy M ; Lytrivi, Irene D. ; Wittlieb-Weber, Carol A. ; Cantor, Ryan ; Singh, Nikki M. ; Atallah, Joseph ; Urschel, Simon ; Singh, Nikki M ; Zhao, Hong ; Motiuk, Jillian ; Kirklin, James K. ; Lytrivi, Irene D

BACKGROUNDArrhythmias can lead to cardiac arrest and heart failure. When intractable, heart transplantation (HTX) can become the only viable treatment. This rare high-risk cohort has not been reported as a distinct group.OBJECTIVEThe purpose of this study was to characterize the outcomes of pediatric patients listed for HTX with the primary indication being malignant arrhythmia (MA).METHODSUsing the Pediatric Heart Transplant Society prospective registry, we identified all patients younger than 18 years listed between 2014 and 2022. MA as the listing indication was categorized into primary tachyarrhythmia (PT), inherited arrhythmia (IA), congenital heart disease, and cardiomyopathy (CM) with secondary arrhythmia. Demographic, listing, and transplant data were analyzed.RESULTSAmong 4630 patients listed and 3317 transplanted, MA was the indication in 63 (1.4%) and 49 (1.5%), respectively. Patients with MA were categorized as PT in 11, IA in 4, congenital heart disease in 6, and CM in 42. Compared with the non-MA cohort, patients listed for MA were older (mean age 10.6 ± 6.2 years vs 6.1 ± 6.2 years; P < .01), more likely to present with cardiac arrest (43% vs 11%; P < .01), and less likely to be in the intensive care unit (40% vs 58%; P < .01) or on inotropes (30% vs 60%; P < .01) at listing. Outcomes including waitlist mortality, transplantation, posttransplant survival, and freedom from rejection were comparable to those of the non-MA cohort.CONCLUSIONPatients with MA constitute a small proportion of those listed for HTX in childhood. CM was the most common category, while IA and PT were rare. Their waitlist mortality and posttransplant outcomes were comparable to those of the non-MA cohort.

2024-10-01·Veterinary Research Communications

A pilot study of the proarrhythmic effects of pimobendan injection in clinically healthy cats

Article

作者: Katagiri, Keisuke ; Miyagawa, Yuichi ; Takemura, Naoyuki ; Ogawa, Mizuki ; Ishizaka, Mio ; Hsu, Huai-Hsun

Pimobendan is not currently approved for use in cats, although its usefulness in feline hypertrophic cardiomyopathy has been suggested. Reports indicate an increase in arrhythmic events following oral administration to healthy cats. Given the greater potency of intravenous administration compared to oral intake, it is conceivable that the incidence of arrhythmias may be increased following pimobendan injection. Therefore, this study aimed to investigate the proarrhythmic effects of pimobendan injection in cats. Five clinically healthy cats underwent physical examination, echocardiography, blood pressure measurements, and 24-hour Holter electrocardiography immediately before and after receiving pimobendan as an intravenous bolus dose of 0.15 mg/kg twice daily for 3 days. Additionally, a 24-hour Holter electrocardiography recording was conducted on the third day of pimobendan or placebo IV administration to assess heart rate, arrhythmias, and heart rate variability. Following pimobendan administration, there was a significant increase in total 24-hour heart rate. Echocardiography revealed a significant increase in mitral valve annulus systolic velocity (S') on the ventricular septal wall side, indicative of enhanced contractility. Only one cat exhibited paroxysmal ventricular tachycardia and an increase in the frequency of arrhythmic events. Conversely, in the remaining cats, a decreasing trend in the number of arrhythmias was observed. These findings indicate that intravenous administration of pimobendan may not be implicated in the onset of arrhythmias. Nevertheless, further research is warranted to explore the effects of intravenous pimobendan administration in cats with myocardial disease.

2024-10-01·ACG case reports journal

Boulder Dash: Endoscopic Management of Bouveret Syndrome and Gallstone Ileus.

Article

作者: Hirsch, William ; Megna, Bryant ; Azeem, Nabeel

项与阵发性心动过速相关的新闻（医药）

2024-04-17

·BioSpace

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at . Poster Presentation Title: Characterizing Paroxysmal Supraventricular Tachycardia Episodes by Patient-Perceived Episode Duration, Symptoms, and Severity: Longitudinal Patient-Reported Outcomes (Encore) Presenter: Richard L. Sherwood, MD Date and time: April 18, 5:30-6:30pm EST Poster Presentation Title: Assessing the Real-World Impact of Paroxysmal Supraventricular Tachycardia on Quality of Life: A Longitudinal Study With a Focus on Anxiety Burden Presenter: Kathryn A. Wood, PhD, RN, FAHA, FAAN Date and time: April 18, 5:30-6:30pm EST Poster Presentation Title: Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRA-201 (Encore) Presenter: James Nunez, PharmD Date and time: April 18, 5:30-6:30pm EST About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR. Contact: Kim Fox, Vice President, Communications, kfox@milestonepharma.com Investor Relations Chris Calabrese, ccalabrese@lifesciadvisors.com Kevin Gardner, kgardner@lifesciadvisors.com

临床2期AHA会议

2023-04-07

·药智网

最高降幅76.13%！心脏起搏器产品分析，注册、中标、创新…

自2020年新冠疫情爆发以来，国家对医疗器械行业发展重视程度显著提高，在政策方面给予较大支持。国家鼓励创新，从加快器械审批流程、财政税收支持、采购优先选择国货和出台国家级的采购计划等四个方面刺激市场需求，助力医疗器械行业发展。国家正着手加快补齐我国高端医疗器械短板，加快关键核心技术攻关，突破技术装备瓶颈，力争实现高端医疗器械自主可控。医疗器械相关监管部门也在不断的深化医疗体制改革对医疗器械行业制定了更为细致、明确的监管要求，保障行业发展。为客观评价心脏起搏器医疗器械产品发展水平和发展质量，重庆康洲大数据（集团）有限公司依托其自主研发的国内顶尖医疗器械大数据服务平台药智器械，凭借总体趋势、企业分布、创新能力、注册信息等信息从多维度解析当前心脏起搏器医疗器械产品发展趋势和行业现状，为心脏起搏器医疗器械产品发展提供数据支持。一、产品概述人工心脏起搏器（artificial cardiac pacemaker），一种医用电子仪器，按照规定的程序发放电脉冲，通过导线及电极刺激心脏，使之搏动，以治疗某些严重的心律失常，如窦房结功能障碍、房室传导阻滞、阵发性心动过速等。急症治疗用的临时性起搏装置，多采用导线经皮联接体外佩带的起搏器。心脏起搏器是由电池和电路组成的脉冲发生器，能定时发放一定频率的脉冲电流，通过起搏电极导线传输到心房或心室肌，使局部的心肌细胞受到刺激而兴奋，兴奋通过细胞间的传导扩散传布，导致整个心房和（或）心室的收缩，心脏的电信号使它跳动。当运行时，心脏跳动加速；当睡眠时，心脏跳动减慢。如果心电系统异常，心脏跳得很慢，甚至可能完全停止。人工心脏起膊器发出有规律的电脉冲，能使心脏保持跳动。二、产品注册2.1 总体趋势截至2022年底，心脏起搏器医疗器械产品注册总数为59件。其中，国产产品有8件，占比13%。2019-2021年总体注册数量呈上升趋势，2022年注册数量最少，为四年最低点。虽然心脏起搏器医疗器械产品的国产占比率在逐年增加，但进口产品依旧占据超过三分之二的份额。2.2 心脏起搏器医疗器械产品国产&进口产品注册情况据统计，2019-2021年，心脏起搏器医疗器械产品大多依赖进口注册；从2020年开始，国产产品逐渐进入市场，进口产品每年注册数量占总数的80%左右。2.3 国产心脏起搏器医疗器械产品注册省份分布情况截至2022年底，仅有三个省份注册心脏起搏器医疗器械产品，总体注册数量较少。注册数量最多的省份是陕西省7件，占总数的77%。注册产品数量排名前三的省份依次是：陕西省7件，上海市1件，广东省1件。2.4 国产心脏起搏器医疗器械产品注册人情况据统计，截至2022年底，国产心脏起搏器医疗器械产品注册数量排名第一的企业是位于陕西省的乐普医学电子仪器股份有限公司，产品注册数为6件。2.5进口心脏起搏器医疗器械注册产品来源国家分布情况据统计，截至2022年底，共有四个国家在我国境内注册心脏起搏器医疗器械产品。注册产品数量最多的国家是美国31件，占总数的62%。注册产品数量从多到少的国家排名依次是：美国31件，德国11件，意大利和荷兰均为4件。2.6 进口心脏起搏器医疗器械产品注册人情况据统计，截至2022年底，进口心脏起搏器医疗器械产品注册数量排名第一的企业是百多力欧洲股份两合公司BIOTRONIK SE & Co.KG，产品注册数为11件。三、创新能力2022年，国家药监局按照《创新医疗器械特别审查程序》、《医疗器械优先审批程序》进行相关产品的审查工作，共收到创新医疗器械特别审批申请343项，比2021年增加37.8%。其中，68项获准进入创新医疗器械特别审查程序。据统计，截至2022年12月31日，全国共有54个创新医疗器械产品获批上市。其中，有四件心脏起搏器医疗器械产品通过创新医疗器械特别审查程序：四、市场情况4.1 中标金额趋势2020年，在全球疫情的影响下，对心脏起搏器类耗材产品需求依旧在逐渐的增加。2018-2022年中，2020年是近五年来中标金额最高的一年，达到了11084.53万元，年增长率为100.4%。而2021年起，连续两年中标金额都下降，2022年年增长率为-52.8%，为近五年的最低点。4.2 心脏起搏器类耗材各省份采购情况（top10）据统计，截至2022年底，从各省采购心脏起搏器类耗材金额的排名来看，新疆维吾尔自治区以4880.99万元排名第一，其余前五分别为甘肃省（4490.66万元）、山东省（2967.67万元）、陕西省（2576.21万元）、湖南省（2568.83万元）。4.3 心脏起搏器类耗材中标企业省份分布情况据统计，截至2022年底，参加心脏起搏器类耗材中标的企业共有55家，大多数分布在上海市和北京市；主要企业为美敦力、圣犹达等境外代理企业，占全国市场份额的85%，国内企业较少。五、小结从产品注册情况来看，2019-2021年，心脏起搏器医疗器械产品大多依赖进口注册，从2020年开始，国产产品逐渐进入市场，进口产品每年注册数量占总数的80%左右。从产业规模来看，我国心脏起搏器医疗器械产品主要来源于美国、德国等境外企业。目前国内注册产品数量最多的省份是陕西省，占全国市场份额的77%左右。从心脏起搏器耗材产品中标情况来看，中标企业主要为外资企业，目前我国集中采购心脏起搏器耗材产品主要是进口产品，供应商更多为国外企业。2023年4月1日起，广东牵头的心脏起搏器类医用耗材联盟集采中选结果在广东全面落地执行。心脏起搏器中选价格每台在7125元-172970元不等，最便宜的每台只需7125元；按注册证数计算，报名产品共有152个，中选产品150个，中选率高达98.68%；按企业数计算，7家进口企业和3家国产企业100%中选。本次集采，平均降幅43.09%，最高降幅76.13%。其中，患者受益最大的是植入式心律转复除颤器类产品，广东价格由原平均每台14.06万元降至6.51万元，每台可节省患者耗材费用7.55万元；降幅最大的是植入式心脏起搏器类产品，广东价格由原平均 8.55万元下降至2.04万元，每台可节省患者耗材费用6.51万元。按照2023年首年预采购量近1.3万台计算，预计全省年节约费用近3亿元，在充分满足医疗机构复杂多样临床需求的同时实现了以量换价，有效减轻了群众费用负担，大大提高了心脏起搏器类产品临床使用的延续性和可及性。来源 | 药智器械（药智网获取授权转载）撰稿 | 青田责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）点击阅读原文，申请药智器械试用哦

带量采购

2022-05-27

·BioSpace

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 27, 2022

MONTREAL and CHARLOTTE, N.C., May 27, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone's common stock on May 16, 2022. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by Milestone's Compensation Committee and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 2.0833% of the original number of shares vesting each month thereafter on the same day of the month as the employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit and follow the Company on Twitter at @MilestonePharma. Contact: David Pitts Argot Partners 212-600-1902 david@argotpartners.com View original content to download multimedia: SOURCE Milestone Pharmaceuticals, Inc. Company Codes: NASDAQ-NMS:MIST